Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 97 companies made new 52-week lows.
NextCure Presents Initial Data From Clinical Trial Of NC762 And A Trial In Progress Poster For NC410 Combo At The 2022 Society For Immunotherapy Of Cancer Annual Meeting
NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today
Ladenburg Thalmann Downgrades NextCure to Neutral
Ladenburg Thalmann analyst Aydin Huseynov downgrades NextCure (NASDAQ:NXTC) from Buy to Neutral.
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 236 companies set new 52-week lows.
Needham Maintains Buy on NextCure, Lowers Price Target to $6
Needham analyst Gil Blum maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $12 to $6.